/Companies

Biohaven

NYSE: BHVN

Connecticut, US · Founded 2022 · 405 employees on LinkedIn · 5 known investors

Find your way into Biohaven

Sign up to see every warm intro you have to Biohaven

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Biohaven team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Biohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy. The company operates as a modern publicly traded entity and was acquired by Pfizer in May 2022 for approximately $13 billion.

Founders & leadership

VCVlad Coric, M.D.
Vlad Coric, M.D.Chairman & Chief Executive OfficerVlad Coric holds an M.D. and brings over 25 years of clinical and research experience in neuroscience and related therapeutic areas; as CEO and Chairman of Biohaven, he led the development of Nurtec ODT for migraine treatment, which contributed to the company's acquisition by Pfizer in 2022.

Investors · 5

Valuation · disclosed

Disclosed events
$413.4Mvaluation at IPOOct 2022 · $10.50/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Related companies · 2

Companies working in the same space as Biohaven.

Frequently asked questions

What does Biohaven do?
Biohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy. The company operates as a modern publicly traded entity and was acquired by Pfizer in May 2022 for approximately $13 billion.
Who are Biohaven's investors?
Biohaven's investors include Connecticut Innovations, Oberland Capital, RA Capital, Sixth Street, BlackRock.
Where is Biohaven headquartered?
Biohaven is headquartered in Connecticut, US.